These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15985000)

  • 1. Successful treatment of chronic hepatitis D with a short course of peginterferon alfa-2a.
    Ferenci P; Formann E; Romeo R
    Am J Gastroenterol; 2005 Jul; 100(7):1626-7. PubMed ID: 15985000
    [No Abstract]   [Full Text] [Related]  

  • 2. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
    Gish RG; Lau DT; Schmid P; Perrillo R
    Am J Gastroenterol; 2007 Dec; 102(12):2718-23. PubMed ID: 17662102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the addition of lamivudine to peginterferon alpha-2a sustain response rates in HBeAg-negative hepatitis B?
    Cooksley G
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):12-3. PubMed ID: 16265091
    [No Abstract]   [Full Text] [Related]  

  • 4. Peginterferon alfa-2a in patients with chronic hepatitis C.
    Zeuzem S; Feinman SV; Rasenack J; Heathcote EJ; Lai MY; Gane E; O'Grady J; Reichen J; Diago M; Lin A; Hoffman J; Brunda MJ
    N Engl J Med; 2000 Dec; 343(23):1666-72. PubMed ID: 11106715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.
    Andriulli A; Mangia A
    N Engl J Med; 2007 Oct; 357(16):1660; author reply 1661-2. PubMed ID: 17942881
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa.
    Maraolo AE; Minervini F; Tosone G
    Aliment Pharmacol Ther; 2015 Mar; 41(6):595. PubMed ID: 25659214
    [No Abstract]   [Full Text] [Related]  

  • 7. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.
    Liu CH; Chen DS; Kao JH
    N Engl J Med; 2007 Oct; 357(16):1661; author reply 1661-2. PubMed ID: 17948345
    [No Abstract]   [Full Text] [Related]  

  • 8. Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a.
    Lamb MW; Martin NE
    Ann Pharmacother; 2002 May; 36(5):933-5. PubMed ID: 12014351
    [No Abstract]   [Full Text] [Related]  

  • 9. Pegylated interferon therapy of chronic hepatitis D: in need of revision.
    Rizzetto M; Smedile A
    Hepatology; 2015 Apr; 61(4):1109-11. PubMed ID: 25348580
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa--authors' reply.
    Koh C; Heller T
    Aliment Pharmacol Ther; 2015 Mar; 41(6):595-6. PubMed ID: 25659215
    [No Abstract]   [Full Text] [Related]  

  • 11. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months.
    Ormeci N; Bölükbaş F; Erden E; Coban S; Ekiz F; Erdem H; Palabıyıkoğlu M; Beyler AR; Balık I; Bölükbaş C; Nazlıgül Y; Köklü S
    Hepatogastroenterology; 2011; 58(110-111):1648-53. PubMed ID: 22086695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
    Fried MW; Hadziyannis SJ
    Semin Liver Dis; 2004; 24 Suppl 2():47-54. PubMed ID: 15346246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.
    Everson GT; Balart L; Lee SS; Reindollar RW; Shiffman ML; Minuk GY; Pockros PJ; Govindarajan S; Lentz E; Heathcote EJ
    Aliment Pharmacol Ther; 2008 Apr; 27(7):542-51. PubMed ID: 18208570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C.
    Ferenci P
    Int J Clin Pract; 2003 Sep; 57(7):610-5. PubMed ID: 14529063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
    Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J
    N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon alfa-2a (Pegasys) for chronic hepatitis C.
    Med Lett Drugs Ther; 2003 Mar; 45(1151):19-20. PubMed ID: 12612502
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiviral effect of peginterferon alfa-2b and alfa-2a compared.
    Jansen PL; Reesink HW
    J Hepatol; 2006 Aug; 45(2):172-3. PubMed ID: 16797101
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL
    Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.